NCT03468933View on ClinicalTrials.gov

Fibrinolysis Compared to Thoracoscopy for Pleural Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
Pleural InfectionEmpyemaPleural DiseasesParapneumonic Effusion
Interventions
DRUG

tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)

Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose

PROCEDURE

Medical Thoracoscopy

Medical thoracoscopy will be performed as per standard protocols.

Trial Locations (1)

70112

Tulane Medical Center Tulane University Section of Pulmonary DiseasesTulane University Section of Pulmonary Diseases, New Orleans

All Listed Sponsors
lead

Tulane University

OTHER

NCT03468933 - Fibrinolysis Compared to Thoracoscopy for Pleural Infection | Biotech Hunter | Biotech Hunter